Skip NavigationSkip to Content

Relation of Quantitative Histologic and Radiologic Breast Tissue Composition Metrics With Invasive Breast Cancer Risk

  1. Author:
    Abubakar, Mustapha
    Fan, Shaoqi
    Bowles, Erin Aiello
    Widemann, Lea
    Duggan, Maire A.
    Pfeiffer, Ruth M.
    Falk, Roni T.
    Lawrence,Scott
    Richert-Boe, Kathryn
    Glass, Andrew G.
    Kimes, Teresa M.
    Figueroa, Jonine D.
    Rohan, Thomas E.
    Gierach, Gretchen L.
  2. Author Address

    NCI, Div Canc Epidemiol & Genet, NIH, 9609 Med Ctr Dr, Rockville, MD 20850 USA.Kaiser Permanente, Washington Hlth Res Inst, Seattle, WA USA.Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada.Leidos Biomed Res Inc, Mol & Digital Pathol Lab, Canc Genom Res Lab, Frederick, MD USA.Kaiser Permanente, Ctr Hlth Res, Portland, OR USA.Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland.Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
    1. Year: 2021
    2. Date: Jun
    3. Epub Date: 2021 02 06
  1. Journal: JNCI cancer spectrum
  2. OXFORD UNIV PRESS,
    1. 5
    2. 3
  3. Type of Article: Article
  4. Article Number: pkab015
  5. ISSN: 2515-5091
  1. Abstract:

    Background: Benign breast disease (BBD) is a strong breast cancer risk factor, but identifying patients that might develop invasive breast cancer remains a challenge. Methods: By applying machine-learning to digitized hematoxylin and eosin-stained biopsies and computer-assisted thresholding to mammograms obtained circa BBD diagnosis, we generated quantitative tissue composition metrics and determined their association with future invasive breast cancer diagnosis. Archival breast biopsies and mammograms were obtained for women (18-86 years of age) in a case-control study, nested within a cohort of 15 395 BBD patients from Kaiser Permanente Northwest (1970-2012), followed through mid-2015. Patients who developed incident invasive breast cancer (ie, cases; n = 514) and those who did not (ie, controls; n = 514) were matched on BBD diagnosis age and plan membership duration. All statistical tests were 2-sided. Results: Increasing epithelial area on the BBD biopsy was associated with increasing breast cancer risk (odds ratio [OR](Q4 vs Q1) = 1.85, 95% confidence interval [CI] = 1.13 to 3 . 04 ; P-trend = .02). Conversely, increasing stroma was associated with decreased risk in nonproliferative, but not proliferative, BBD (P-heterogeneity = .002). Increasing epithelium-to-stroma proportion (ORQ4 vs Q1 = 2.06, 95% CI =1.28 to 3.33; P-trend = .002) and percent mammographic density (MBD) (OR (Q4 vs Q1) = 2.20, 95% CI = 1.20 to 4.03; P-trend = .01) were independently and strongly predictive of increased breast cancer risk. In combination, women with high epithelium-to-stroma proportion and high MBD had substantially higher risk than those with low epithelium-to-stroma proportion and low MBD (OR = 2.27, 95% CI = 1.27 to 4.06; P-trend = .005), particularly among women with nonproliferative (P-trend = .01) vs proliferative (P-trend = .33) BBD. Conclusion: Among BBD patients, increasing epithelium-to-stroma proportion on BBD biopsies and percent MBD at BBD diagnosis were independently and jointly associated with increasing breast cancer risk. These findings were particularly striking for women with nonproliferative disease (comprising approximately 70% of all BBD patients), for whom relevant predictive biomarkers are lacking.

    See More

External Sources

  1. DOI: 10.1093/jncics/pkab015
  2. PMID: 33981950
  3. PMCID: PMC8103888
  4. WOS: 000664188700006

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel